Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Accounts Payables (2022 - 2025)

NewAmsterdam Pharma's Accounts Payables history spans 4 years, with the latest figure at $9.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 34.08% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $9.0 million, down 34.08%, while the annual FY2025 figure was $9.0 million, 34.08% down from the prior year.
  • Accounts Payables for Q4 2025 was $9.0 million at NewAmsterdam Pharma, up from $3.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $18.9 million in Q4 2022 and bottomed at $3.6 million in Q3 2025.
  • The 4-year median for Accounts Payables is $9.7 million (2024), against an average of $9.8 million.
  • The largest YoY upside for Accounts Payables was 79.34% in 2025 against a maximum downside of 65.67% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $18.9 million in 2022, then plummeted by 39.62% to $11.4 million in 2023, then increased by 19.39% to $13.6 million in 2024, then crashed by 34.08% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Accounts Payables are $9.0 million (Q4 2025), $3.6 million (Q3 2025), and $9.5 million (Q2 2025).